Navigation Links
Harvest Technologies Announces Initial Enrollment in Its REVIVE-1 Trial (REtrograde Vascular Infusion of BMAC to ImproVe Heart FailurE)
Date:4/20/2011

PLYMOUTH, Mass., April 20, 2011 /PRNewswire/ -- Harvest Technologies Corp. (www.harvesttech.com) announced today that the first twelve patients of its sixty patient Heart Failure trial have been enrolled at Medanta-the Medicity in Gurgaon INDIA.

The trial is intended to evaluate the safety and clinical effect of Harvest's BMAC autologous cell composition to treat patients with Congestive Heart Failure (CHF) when using a minimally invasive retrograde coronary sinus delivery.  This is a randomized, controlled design treating both ischemic and non-ischemic heart failure patients.  Patient enrollment will take place in sites in India, Germany and Peru and will feature electronic data entry with its data coordinating center at the University of Utah. The overall trial will be directed by Amit Patel, MD, Director, Center for Cardiac Cell Therapy at the University of Utah. The trial is being conducted in compliance with the United States FDA clinical trial regulations, ICH GCP, local IRB or IEC regulations and the "Declaration of Helsinki" and a Data Safety Monitoring Board (DSMB) will monitor adverse events.  

Congestive Heart Failure is a persistent and relentless problem, which affects over an estimated 20 million patients world-wide. It occurs when the heart's ability to pump blood is so impaired that "systemic perfusion is inadequate to meet the body's demands" and this condition cannot be mediated by either by medication or surgical or endovascular intervention. A major advance in treatment is needed which could reverse this condition and in ischemic patients initiate neovascularization to restore perfusion within the affected area of the myocardium.

While there are several cardiac trials that have shown a clinical effect arising from the delivery of bone marrow cells through the coronaries, this approach offers several advantages according to Dr. Patel. "This novel delivery approach has several advantages over the antigrade approach. It is a safer approach into the heart, allows for the delivery of significantly more cells and in our experience results in substantially greater cell retention. In addition, the Harvest rapid processing of bone marrow in the procedure room could allow the procedure to be done on an outpatient basis."

"Congestive Heart Failure is a cruel, debilitating disease effecting over 20 million people. Although many of the cell therapy studies have demonstrated promise, the improvements shown have been less than ideal. We are extremely optimistic that this study will show the improvement in clinical results that can eventually lead to a treatment option for this patient population," states Gary Tureski, President Harvest Technologies.

Harvest Technologies is a privately held company based in Plymouth, Mass.

Contact:

P. Kevin Benoit; VP / General Manager Strategic Business Development – 508-732-7500


'/>"/>
SOURCE Harvest Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Nanonets give rust a boost as agent in water splittings hydrogen harvest
2. Scientists produce transparent, light-harvesting material
3. Gloabl Harvest Initiative: Taking Down Fences To Meet Future Needs
4. Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia
5. Harvest Technologies Announces Completion of Patient Enrollment in its Randomized, Controlled, Double Blind Multicenter IDE Non-Reconstructable Critical Limb Ischemia Trial
6. UK scientists developing intelligent harvesting robot to save farms up to 100,000 a year
7. Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
8. Scientists determine the structure of highly efficient light-harvesting molecules in green bacteria
9. Mach One Corporation Completes Acquisition of Ceres Organic Harvest, Inc.
10. Mach One Corporation Signs Definitive Agreement to Acquire Ceres Organic Harvest, Inc.
11. Life Technologies to Present at Bairds 2011 Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016 CytRx Corporation (NASDAQ: CYTR ... oncology, today announced the appointment of Earl Warren ... and private healthcare investor, to its Board of Directors. ... clinical and strategic experience at the highest level," said ... "As one of the world,s leading orthopedic surgeons, Dr. ...
(Date:12/2/2016)... NC (PRWEB) , ... December 01, 2016 , ... ... US Computational Science Symposium (CSS) and the popularity of US Single Day Events ... take place in early Summer 2018, in Raleigh, NC. Topics of the pharmaceutical ...
(Date:12/2/2016)... Boston, MA (PRWEB) , ... December 02, 2016 , ... ... of Light Event on December 3rd, 2016. The event, which is held on ... NTI’s work with helping Americans with Disabilities back into the workplace. Suitable Technologies is ...
(Date:11/30/2016)... CLEVELAND , Nov. 30, 2016  GenomOncology today announced ... Vice President of Medical Affairs.  Dr. Coleman ... enhancing the company,s proprietary knowledge-enabled platform. The GenomOncology software suite ... of genetic sequencing data and clinical decision support, from quality ... , ...
Breaking Biology Technology:
(Date:11/29/2016)... -- Nearly one billion matches per second with DERMALOG,s high-speed ... ... DERMALOG is Germany's largest Multi-Biometric supplier: ... (PRNewsFoto/DERMALOG Identification Systems) ... is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is part ...
(Date:11/21/2016)... 21, 2016   Neurotechnology , a provider ... today announced that the MegaMatcher On Card fingerprint ... for the NIST Minutiae Interoperability Exchange (MINEX) ... mandatory steps of the evaluation protocol. ... test of fingerprint templates used to establish compliance ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):